Background: Patients with end-stage kidney disease (ESKD) on maintenance dialysis have a high risk of developing hyperkalemia. In addition to traditional approaches, a new option for the management of patients on dialysis includes the use of a potassium binder, sodium zirconium cyclosilicate (SZC). We evaluated the effect and safety of SZC in patients with chronic PD. Objective: To present a case series that illustrates the real-world use of new potassium-binders in hyperkalemic patients on peritoneal dialysis. Methods: This case series collected 9 patients on PD with baseline potassium values > 5.5 mmol/l and who were treated with SZC 5 g once a day. Data were collected at baseline and at 1, 2, and 3 months after initiation of treatment. Results: The median age of patients was 64.5 years and the median duration of observation was 90 ± 5 days. It was observed that median serum potassium decreased (5.8 mmol/l at baseline with a range of 5.8 mmol/L - 6.8 mmol/L versus 4.5 in the third month with a range of 3.6 mmol/L - 5.3 mmol/L) after SZC treatment. Adverse events were observed in 2 (22.2%). The unique adverse event was constipation and presented in 2 patients (22.2%). Constipation was mild and transient during the observation period. No adverse events of special interest were reported. Conclusion: Normokalemia was established and maintained in this series of patients treated with SZC. No episodes of hyper- or hypo-kalemia were observed. SCZ had a good safety profile and was well tolerated over 3 months.
References
[1]
Einhorn, L.M., Zhan, M., Hsu, V.D., Walker, L.D., Moen, M.F., Seliger, S.L., etal. (2009) The Frequency of Hyperkalemia and Its Significance in Chronic Kidney Disease. ArchivesofInternalMedicine, 169, 1156-1162. https://doi.org/10.1001/archinternmed.2009.132
[2]
Tandukar, S. and Fried, L.F. (2018) Dyskalemia in Chronic Kidney Disease: How Concerned Should We Be? Nephron, 140, 58-62. https://doi.org/10.1159/000490008
Musso, C.G. (2004) Potassium Metabolism in Patients with Chronic Kidney Disease. Part II: Patients on Dialysis (Stage 5). InternationalUrologyandNephrology, 36, 469-472. https://doi.org/10.1007/s11255-004-6194-y
[5]
An, J., Lee, J., Jeon, H., Kim, D., Oh, Y., Kim, Y., etal. (2012) Severe Hyperkalemia Requiring Hospitalization: Predictors of Mortality. CriticalCare, 16, R225. https://doi.org/10.1186/cc11872
Bianchi, S., Aucella, F., De Nicola, L., Genovesi, S., Paoletti, E. and Regolisti, G. (2019) Management of Hyperkalemia in Patients with Kidney Disease: A Position Paper Endorsed by the Italian Society of Nephrology. JournalofNephrology, 32, 499-516. https://doi.org/10.1007/s40620-019-00617-y
[8]
Bansal, S. and Pergola, P.E. (2020) Current Management of Hyperkalemia in Patients on Dialysis. Kidney International Reports, 5, 779-789. https://doi.org/10.1016/j.ekir.2020.02.1028
[9]
Ni, Z., Lu, R., Xu, X., Bian, X., Zhou, Z., Yang, J., etal. (2023) DIALIZE China: A Phase IIIb, Randomized, Placebo-Controlled Study to Reduce Predialysis Hyperkalemia with Sodium Zirconium Cyclosilicate in Chinese Patients. ClinicalTherapeutics, 45, 633-642. https://doi.org/10.1016/j.clinthera.2023.04.014
[10]
Ford, M., Fishbane, S., Spinowitz, B., Rastogi, A., Guzman, N. and McCafferty, K. (2021) Effectiveness of Sodium Zirconium Cyclosilicate in Hemodialysis Patients with Severe Hyperkalemia. KidneyInternationalReports, 6, 3074-3078. https://doi.org/10.1016/j.ekir.2021.09.004
[11]
Spinowitz, B., McCafferty, K., Fishbane, S., Fukagawa, M., Guzman, N., Ford, M., etal. (2021) Dose Effect Analysis of Sodium Zirconium Cyclosilicate in Hemodialysis Patients. HemodialysisInternational, 26, 274-277. https://doi.org/10.1111/hdi.12983
[12]
Fishbane, S., Ford, M., Fukagawa, M., McCafferty, K., Rastogi, A., Spinowitz, B., etal. (2022) Potassium Responses to Sodium Zirconium Cyclosilicate in Hyperkalemic Hemodialysis Patients: Post-Hoc Analysis of DIALIZE. BMCNephrology, 23, Article No. 59. https://doi.org/10.1186/s12882-021-02569-7
[13]
Yu, H., Lu, X., Su, C., Tang, W. and Wang, T. (2014) Potassium Metabolism in Continuous Ambulatory Peritoneal Dialysis Patients. RenalFailure, 36, 748-754. https://doi.org/10.3109/0886022x.2014.884379
[14]
Yusuf, A.A., Hu, Y., Singh, B., Menoyo, J.A. and Wetmore, J.B. (2016) Serum Potassium Levels and Mortality in Hemodialysis Patients: A Retrospective Cohort Study. AmericanJournalofNephrology, 44, 179-186. https://doi.org/10.1159/000448341
[15]
Jing, S., Kezhou, Y., Hong, Z., Qun, W. and Rong, W. (2010) Effect of Renin-Angiotensin System Inhibitors on Prevention of Peritoneal Fibrosis in Peritoneal Dialysis Patients. Nephrology, 15, 27-32. https://doi.org/10.1111/j.1440-1797.2009.01162.x
[16]
Bomback, A.S. (2016) Mineralocorticoid Receptor Antagonists in End-Stage Renal Disease: Efficacy and Safety. BloodPurification, 41, 166-170. https://doi.org/10.1159/000441262
[17]
Garlo, K.G., Bates, D.W., Seger, D.L., Fiskio, J.M. and Charytan, D.M. (2018) Association of Changes in Creatinine and Potassium Levels after Initiation of Renin Angiotensin Aldosterone System Inhibitors with Emergency Department Visits, Hospitalizations, and Mortality in Individuals with Chronic Kidney Disease. JAMANetworkOpen, 1, e183874. https://doi.org/10.1001/jamanetworkopen.2018.3874
[18]
Yancy, C.W., Jessup, M., Bozkurt, B., etal. (2013) 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Journal of the American College of Cardiology, 62, e147-e239. https://doi.org/10.1016/j.jacc.2013.05.019
[19]
Kalantar-Zadeh, K. and Fouque, D. (2017) Nutritional Management of Chronic Kidney Disease. NewEnglandJournalofMedicine, 377, 1765-1776. https://doi.org/10.1056/nejmra1700312
[20]
Carrero, J.J., González-Ortiz, A., Avesani, C.M., Bakker, S.J.L., Bellizzi, V., Chauveau, P., et al. (2020) Plant-Based Diets to Manage the Risks and Complications of Chronic Kidney Disease. NatureReviewsNephrology, 16, 525-542. https://doi.org/10.1038/s41581-020-0297-2
[21]
Noori, N., Kalantar-Zadeh, K., Kovesdy, C.P., Murali, S.B., Bross, R., Nissenson, A.R., etal. (2010) Dietary Potassium Intake and Mortality in Long-Term Hemodialysis Patients. AmericanJournalofKidneyDiseases, 56, 338-347. https://doi.org/10.1053/j.ajkd.2010.03.022
[22]
Saglimbene, V.M., Wong, G., Ruospo, M., Palmer, S.C., Garcia-Larsen, V., Natale, P., etal. (2019) Fruit and Vegetable Intake and Mortality in Adults Undergoing Maintenance Hemodialysis. ClinicalJournaloftheAmericanSocietyofNephrology, 14, 250-260. https://doi.org/10.2215/cjn.08580718
Kalantar‐Zadeh, K., Tortorici, A.R., Chen, J.L.T., Kamgar, M., Lau, W., Moradi, H., etal. (2015) Dietary Restrictions in Dialysis Patients: Is There Anything Left to Eat? SeminarsinDialysis, 28, 159-168. https://doi.org/10.1111/sdi.12348
[25]
Harel, Z., Harel, S., Shah, P.S., Wald, R., Perl, J. and Bell, C.M. (2013) Gastrointestinal Adverse Events with Sodium Polystyrene Sulfonate (Kayexalate) Use: A Systematic Review. TheAmericanJournalofMedicine, 126, 264.E9-264.E24. https://doi.org/10.1016/j.amjmed.2012.08.016
[26]
Yuan, C.M., Nee, R., Little, D.J. and Abbott, K.C. (2013) Incidence of Sodium Polystyrene Sulfonate-Associated Colonic Necrosis. TheAmericanJournalofMedicine, 126, e13. https://doi.org/10.1016/j.amjmed.2013.02.034
[27]
Stavros, F., Yang, A., Leon, A., Nuttall, M. and Rasmussen, H.S. (2014) Characterization of Structure and Function of ZS-9, a K+ Selective Ion Trap. PLOS ONE, 9, e114686. https://doi.org/10.1371/journal.pone.0114686
[28]
de Francisco, A., Rasmussen, H., Lavin, P., Singh, B., Yang, A., Mann, J., etal. (2015) Normalization of Serum Bicarbonate with Sodium Zirconium Cyclosilicate (ZS-9) in the Phase 3 Randomized, Double-Blind, Placebo-Controlled Harmonize Study. NephrologyDialysisTransplantation, 30, iii6. https://doi.org/10.1093/ndt/gfv137.02
[29]
Anker, S.D., Kosiborod, M., Zannad, F., Piña, I.L., McCullough, P.A., Filippatos, G., etal. (2015) Maintenance of Serum Potassium with Sodium Zirconium Cyclosilicate (ZS‐9) in Heart Failure Patients: Results from a Phase 3 Randomized, Double‐Blind, Placebo‐Controlled Trial. EuropeanJournalofHeartFailure, 17, 1050-1056. https://doi.org/10.1002/ejhf.300
[30]
Kashihara, N., Nishio, T., Saka, Y., etal. (2019) Subpopulation Analysis of the Efficacy of Sodium Zirconium Cyclosilicate Hydrate (SZC) in Japanese Patients during the Correction Phase of a Dose Response Study. 62ndAnnualMeetingoftheJapaneseSocietyofNephrology, Nagoya, 21-23 June 2019.
Zeng, Q., Zhou, X. and Xu, G. (2019) Safety Evaluation and Cardiovascular Effect of Additional Use of Spironolactone in Hemodialysis Patients: A Meta-Analysis. DrugDesign,DevelopmentandTherapy, 13, 1487-1499. https://doi.org/10.2147/dddt.s189454
[33]
Epstein, M., Reaven, N.L., Funk, S.E., etal. (2015) Evaluation of the Treatment Gap between Clinical Guidelines and the Utilization of Renin-Angiotensin-Aldosterone System Inhibitors. The American Journal of Managed Care, 21, S212-S220.
[34]
Hoppe, L.K., Muhlack, D.C., Koenig, W., Carr, P.R., Brenner, H. and Schöttker, B. (2018) Association of Abnormal Serum Potassium Levels with Arrhythmias and Cardiovascular Mortality: A Systematic Review and Meta-Analysis of Observational Studies. CardiovascularDrugsandTherapy, 32, 197-212. https://doi.org/10.1007/s10557-018-6783-0
[35]
Ash, S.R., Singh, B., Lavin, P.T., Stavros, F. and Rasmussen, H.S. (2015) A Phase 2 Study on the Treatment of Hyperkalemia in Patients with Chronic Kidney Disease Suggests That the Selective Potassium Trap, ZS-9, Is Safe and Efficient. KidneyInternational, 88, 404-411. https://doi.org/10.1038/ki.2014.382
